Research workspace

Finance

Public market data, research, and analysis in one place.

Finance home
Back to HK Equities

HK Equities · Finance research note

HKEX 9969 - InnoCare Pharma Ltd.

Research and analysis only
View analysis Browse HK Equities

Evidence and analysis

Research evidence pack

Source-backed valuation visuals

Loading verified snapshot
Loading verified market, valuation, and statement data.

1. Industry Fundamentals

1.1 Cyclicality

The company operates in a cyclical industry sensitive to macroeconomic conditions. Revenue and earnings tend to correlate with broader economic cycles, with periods of expansion driving growth and contractions creating headwinds. Current market capitalisation: 21.85 B.

1.2 Competition

The industry is moderately competitive with established players and meaningful barriers to entry. Beta of N/A suggests moderate market sensitivity. Competitive advantages stem from brand, scale, or regulatory moats.

1.3 Technology

Key technology drivers include digital transformation, operational efficiency, automation. Companies that invest in R&D and adopt new technologies tend to gain market share. The pace of technological change creates both opportunities for innovation and risks of disruption.


2. Company Fundamentals

2.3 Management

RoleMetric
Consensus RatingN/A

2.4 Return

MetricValue
Expected Return (Ann.)93.61%
Risk / Std Dev (Ann.)57.93%

Price Snapshot:

MetricValue
Last Price12.400 HKD
Day Change+0.050 (+0.40%)

DuPont Model Analysis

The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:

ROE = Net Margin × Asset Turnover × Equity Multiplier

The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in HK$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.

DuPont componentCalculationFY2025FY2024
RevenueReported revenueHK$2.37BHK$1.01B
Net incomeReported net incomeHK$642.47MHK$-440.63M
Total assetsYear-end reported balanceHK$10.82BHK$9.41B
Shareholders’ equityYear-end reported balanceHK$7.73BHK$6.73B
Net marginNet income ÷ revenue27.05%-43.65%
Asset turnoverRevenue ÷ total assets0.2194x0.1073x
Equity multiplierTotal assets ÷ shareholders’ equity1.4008x1.3988x
ROENet margin × asset turnover × equity multiplier8.31%-6.55%

Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.

2.5 FCFF DCF Valuation

Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.

Step 1 — Forecast Operating Profit and NOPAT

Reported operating inputValue
RevenueHK$2.37B
Prior annual revenueHK$1.01B
EBITHK$709.87M
Tax rate1.76%
NOPAT = EBIT × (1 − tax rate)HK$697.36M
Forecast start-growth basis15.00%
Forecast policylatest reported annual revenue growth, bounded to -10.00% / 15.00%

Step 2 — Calculate FCFF

Current FCFF building blockValue
NOPATHK$697.36M
Add: depreciation & amortisationHK$118.36M
Less: capital expenditure-HK$70.14M
Less/(add): working-capital cash-flow movementHK$61.11M
Current unlevered FCFFHK$806.70M

Explicit FCFF forecast

Forecast yearRevenue growthNOPATD&ACapexChange in NWCFCFFPresent value
115.00%HK$801.96MHK$136.11M-HK$80.66MHK$70.28MHK$927.70MHK$898.06M
211.88%HK$897.20MHK$152.28M-HK$105.74MHK$78.63MHK$1.02BHK$927.46M
38.75%HK$975.70MHK$165.60M-HK$131.86MHK$85.51MHK$1.09BHK$930.85M
45.62%HK$1.03BHK$174.92M-HK$157.10MHK$90.32MHK$1.14BHK$907.19M
52.50%HK$1.06BHK$179.29M-HK$179.29MHK$92.57MHK$1.15BHK$857.77M

Step 3 — Determine the Discount Rate (WACC)

WACC inputValue
Risk-free rate4.71%
Equity risk premium assumption5.50%
Beta0.39
Cost of equity6.84%
Pre-tax cost of debt4.23%
WACC6.71%
WACC validationrequires assumption review

Step 4 — Estimate Terminal Value

Terminal-value inputValue
Perpetuity growth rate2.50%
Terminal valueHK$27.97B
Implied terminal EV / EBITDA22.30x
Terminal value as % of enterprise value81.72%

Step 5 — Discount Cash Flows to Enterprise Value

Enterprise-value componentValue
Present value of explicit FCFFHK$4.52B
Present value of terminal valueHK$20.22B
Indicated enterprise valueHK$24.74B
Discounting conventionmid-year for explicit FCFF; terminal value discounted at year-end five

Step 6 — Convert Enterprise Value to Equity Value

Equity bridgeValue
Indicated enterprise valueHK$24.74B
Less: gross interest-bearing debtHK$1.29B
Add: cash and equivalentsHK$7.32B
Add: affiliate investmentsHK$0.00
Less: minority interestsHK$22.35M
Indicated common equity valueHK$30.74B

Step 7 — Calculate Indicative Value Per Share

Per-share outputValue
Shares used1,712,336,000.00
Share-count basisreported diluted weighted-average shares
Current market priceHK$14.67
DCF indicative value per shareHK$17.95
Indicative value vs. market price22.38%

Model Integrity Checks

CheckResult
Perpetuity growth is below the risk-free ratepass
Perpetuity growth is below WACCpass
WACC is within the configured operating-company rangereview required
Terminal-year FCFF is positivepass
Terminal capex converges to D&Apass
Terminal-value concentrationwithin review band
Implied price differs from spot by more than 30%within review band

2.6 Investor-Style Research Screen

Educational screenResult
Buffett-inspired cash-quality checks3/4 evidenced checks
Lynch-inspired balance-and-growth checks4/4 evidenced checks

Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:19:59.354846 UTC; latest reported fiscal period: 2025-12-31 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.

2.7 Quantitative Factor Diagnostics

Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.

Estimation inputValue
Regional factor setAsia Pacific ex Japan
Factor-return currencyUSD
Issuer-return basisUSD adjusted total return
Estimation window2025-08-20 to 2026-06-30
Aligned daily observations210
Minimum observation requirement120
Currency conversion for HK listingsHKD adjusted close divided by daily USD/HKD close before simple daily return calculation

Fama–French Three-Factor and Five-Factor Results

DiagnosticFF3FF5
Annualised alpha-44.38%-41.45%
Adjusted R²0.060.06
Annualised residual volatility50.08%49.81%
Factor loading (t-statistic)FF3FF5
Market excess return (Mkt-RF)1.11 (3.90)1.10 (3.58)
Size (SMB)-0.36 (-0.87)-0.50 (-0.95)
Value (HML)0.23 (0.59)-0.01 (-0.03)
Profitability (RMW)NM-0.83 (-1.47)
Investment (CMA)NM-0.04 (-0.06)

Definitions: Mkt-RF is the market return less the risk-free rate; SMB is small minus big; HML is high minus low book-to-market; RMW is robust minus weak profitability; CMA is conservative minus aggressive investment. Factor returns are sourced from the Kenneth R. French Data Library; issuer adjusted-return history is sourced from Yahoo Finance. For Hong Kong listings, adjusted HKD prices are converted into USD with daily USD/HKD closes before return calculation to match the USD regional factor basis. This is an in-sample historical regression; coefficients and t-statistics do not establish causation or predict future returns. This is research and analysis only, not personalized financial advice.

hkexstockequity9969